Advancements in the Treatment of Colorectal Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 193
Special Issue Editor
Interests: colorectal cancer; advanced colorectal surgery; advanced nutritional support; perineal disease; ERAS; advanced endoscopy
Special Issue Information
Dear Colleagues,
This Special Issue spotlights advances transforming colorectal cancer (CRC) care—from prevention to survivorship—through precision and personalized medicine. Enhanced screening, risk stratification, and genomic profiling enable biomarker-driven treatment selection, while AI augments imaging, pathology, and real-time decision support. In metastatic CRC, multidisciplinary care integrates metastasectomy, ablative techniques, stereotactic radiotherapy, hepatic–arterial infusion, and advanced chemotherapy combinations tailored by tumor biology.
Translational breakthroughs include liquid biopsy, proteomics profiling, and circulating tumor DNA for minimal residual disease monitoring, resistance mapping, and dynamic therapy adaptation. The issue examines differential biology of right- versus left-sided tumors, sequencing of perioperative therapy, and the evolving roles of targeted agents (RAS/BRAF/HER2 and KRAS G12C) and immunotherapy in MSI-H/dMMR disease. Across the continuum, precision medicine frameworks align with personalized care to mitigate toxicity, enhance quality of life, and address health equity. Collectively, these studies define next-generation, data-driven standards poised to elevate CRC outcomes. All in all, ‘From lab evidence to clinical practices’.
Prof. Dr. Andee Dzulkarnaen Zakaria
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- genomic profiling
- advanced nutritional support
- AI
- MDT
- adjuvant therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
